The Globe and Mail reports in its Friday, Oct. 4, edition that Raymond James analyst Michael Freeman, following Thursday's DRI Healthcare Trust's announcement of a $57-million (U.S.) deal with Editas Medicine for a share of its annual licence fees for the Cas9 gene-editing technology, raised his unit target to $23 (Canadian) from $20 (Canadian) with an "outperform" recommendation. Analysts on average target the units at $18.68 (Canadian). Mr. Freeman says in a note, "We like deal's elegant structure, its engagement with a highly innovative counter party (potential for repeat business), and what it says about DRI's dealmaking engine: it's fully intact, and it's revving high." The Globe reported on March 1 that Raymond James analyst Rahul Sarugaser had raised his recommendation for DRI Healthcare to "strong buy" from "outperform." The units could then be had for $15.65 (Canadian). The Globe reported on Aug. 14 that Stifel analyst Justin Keywood had upgraded his recommendation for DRI Healthcare to "buy" from "hold." The units could then be had for $12.73 (Canadian).